Moderna’s Commitment to Vaccines and Therapeutics Access

December 23, 2020

Moderna is committed to working on multiple levels to optimize the impact of mRNA vaccines and therapeutics. Our philosophy on pricing and access reflects a few basic principles:

  1. Moderna is committed to developing a broad portfolio of vaccines and therapeutic solutions to address epidemiological challenges worldwide.
  2. Moderna will invest in R&D in areas of unmet need.
  3. Moderna will work to include communities that have historically been under-represented in clinical research in our development programs, as well as those that are disproportionately impacted by the respective diseases.
  4. Moderna aims to provide effective and affordable vaccines and therapeutics to all populations.
  5. Moderna will price its products through differential pricing frameworks.
  6. Moderna is committed to participating in key public-private partnerships such as Gavi, the Vaccine Alliance.
  7. Gavi-eligible countries will get Moderna’s lowest prices, and Moderna commits to an annual independent third-party audit on this commitment.